Results from privately held FoldRx Pharmaceuticals Inc.'s pivotal Phase II/III trial showed that tafamidis (Fx-1006A) significantly halts disease progression and reduces the burden of disease in patients with transthyretin (TTR) amyloid polyneuropathy (ATTR-PN), a fatal progressive neurodegenerative orphan disease. (BioWorld Today)
